SOX10通过IRF1-ITGA3/EphA2-FAK途径调节黑色素瘤转移
Ryuya Kaminaka1, Nana Takahashi1, Mayu Nishizawa1
1Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Cancer science
|August 14, 2025
概括
在黑色素瘤中减少SOX10表达通过IRF1-ITGA3/EphA2-FAK通路促进转移. 使用defactinib准焦粘附激酶 (FAK) 为黑色素瘤提供了一个潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 黑色素瘤异质性驱动转移,MITFlow/AXL高细胞与侵入性相关.
- SOX10在黑色素瘤细胞迁移和入侵中的作用背后的分子机制尚未完全理解.
研究的目的:
- 阐明SOX10在黑色素瘤细胞迁移和转移中的下游作用因子和调节途径.
- 为了确定抑制黑色素瘤进展的潜在治疗点.
主要方法:
- 在体和体外分析以确定SOX10敲击调节的基因.
- 研究了ITGA3,EPHA2,IRF1和MAPK信号在黑色素瘤细胞迁移中的作用.
- 用于体内小鼠模型来评估FAK抑制在减少转移中的有效性.
主要成果:
- SOX10 倒置显著丰富了与细胞迁移相关的基因组.
- 确定ITGA3和EPHA2是SOX10介导迁移的关键下游影响者.
- IRF1作为ITGA3和EPHA2的上游调节者;MAPK激活对于EphA2介导的运动性至关重要.
- 用德法提尼布抑制IRF1或抑制FAK显著减少了体内黑色素瘤转移.
结论:
- 减少SOX10表达通过IRF1-ITGA3/EphA2-FAK信号轴促进黑色素瘤转移.
- 抑制FAK是一种有前途的治疗策略,可以对抗黑色素瘤转移.
相关概念视频
MAPK Signaling Cascades
6.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.0K
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Mitogens and the Cell Cycle
6.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.7K
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K


